← Back to Search

Radiation Therapy

Cyberknife for Pancreatic Cancer

N/A

Recruiting

Led By Timothy Chen, MD

Research Sponsored by Capital Health System, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient has a diagnosis of Stage I to Stage III pancreatic cancer cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria and NCCN guidelines, based on radiographic imaging or exploratory laparoscopic surgery, low degree of arterial involvement (CA, CHA, SMA) and no aorta involvement

Patient shows no evidence of disease progression to distant metastasis based on NCCN

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at baseline and then at 3 month intervals.

Awards & highlights

Study Summary

This trial is testing whether a new cancer treatment called SBRT is effective at shrinking tumors and improving quality of life compared to another treatment called IMRT.

Who is the study for?

This trial is for adults over 18 with Stage I to III pancreatic cancer, who can understand the consent process and have an ECOG status of 0-1. They should not be pregnant, must have completed neoadjuvant chemotherapy, and their cancer shouldn't have spread or involve major arteries too much. It's not for those with a short life expectancy or certain medical devices.Check my eligibility

What is being tested?

The trial tests Cyberknife (SBRT) against IMRT in treating borderline resectable or locally advanced pancreatic adenocarcinoma. The goal is to see if SBRT can shrink tumors enough to make them operable and improve quality of life compared to IMRT.See study design

What are the potential side effects?

While specific side effects are not listed here, treatments like Cyberknife may cause fatigue, skin reactions at the treatment site, digestive issues, and could potentially affect nearby organs due to its focused radiation delivery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My pancreatic cancer is confirmed to be Stage I to III with low arterial involvement.

Select...

My cancer has not spread to distant parts of my body.

Select...

I have finished my initial chemotherapy before surgery.

Select...

I am 18 years old or older.

Select...

I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline and then at 3 month intervals.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline and then at 3 month intervals.

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and then at 3 month intervals. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Resectability

Secondary outcome measures

Patient Reported Outcome (General) - European Organization for Research and Treatment of Cancer (EORTC).

Patient Reported Outcome (Specific)European Organization for Research and Treatment of Cancer (EORTC).

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: SBRT (Cyberknife)Experimental Treatment1 Intervention

5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).

Group II: IMRTActive Control1 Intervention

1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Capital Health System, IncLead Sponsor

Timothy Chen, MDPrincipal InvestigatorCapital Health System, Inc

Shirnett Williamson, MDPrincipal InvestigatorCapital Health System, Inc

Media Library

Cyberknife (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04998552 — N/A

Pancreatic Adenocarcinoma Research Study Groups: SBRT (Cyberknife), IMRT

Pancreatic Adenocarcinoma Clinical Trial 2023: Cyberknife Highlights & Side Effects. Trial Name: NCT04998552 — N/A

Cyberknife (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04998552 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies in this medical experiment that participants can join?

"Affirmative. The information on clinicaltrials.gov attests to the active recruitment for this medical trial, which was first put up on June 22nd 2021. 10 participants are needed from 1 site and it has been recently updated as of August 30th 2021."

Answered by AI

How many individuals are currently participating in this trial?

"Correct. According to clinicaltrials.gov, this trial is actively recruiting participants after being initially posted on June 22nd 2021 and most recently updated on August 30th of the same year. Ten individuals are necessary from one medical centre for inclusion in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

2021. "Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04998552.